Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omid Hamid

Showing results (1-10 of 188) with videos related to

Pageof 19
Sort By:
Journal of Drugs in Dermatology : JDD|December 5, 2013
Nonsurgical treatment options for basal cell carcinoma - focus on advanced diseaseGary Goldenberg, Omid Hamid
Clinical & Experimental Metastasis|December 8, 2021
Immunotherapy of cancer in the era of checkpoint inhibitorInderjit Mehmi, Omid Hamid
Journal of Drugs in Dermatology : JDD|November 8, 2013
Identifying patients at risk for recurrent or advanced BCCOmid Hamid, Gary Goldenberg
Expert Opinion on Biological Therapy|February 21, 2013
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapyOmid Hamid, Richard D Carvajal
Clinical Journal of Oncology Nursing|August 4, 2011
Atypical clinical response patterns to ipilimumabBlanca Ledezma, Sandra Binder, Omid Hamid
The Oncologist|March 13, 2020
Intratumoral Immunotherapy-Update 2019Omid Hamid, Rubina Ismail, Igor Puzanov
Seminars in Oncology|November 16, 2010
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockadePeter Boasberg, Omid Hamid, Steven O'Day
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2018
The Need for Neddylation: A Key to Achieving NED in Uveal MelanomaJessica Yang, Omid Hamid, Richard D Carvajal
Cancer|November 16, 2007
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignanciesSteven J O'Day, Omid Hamid, Walter J Urba
Current Oncology Reports|June 5, 2012
Mucosal melanoma: pathogenesis, clinical behavior, and managementMichael A Postow, Omid Hamid, Richard D Carvajal
Pageof 19

Showing results (1-10 of 188) with videos related to

Sort By:
Pageof 19
Journal of Drugs in Dermatology : JDD|December 5, 2013
Nonsurgical treatment options for basal cell carcinoma - focus on advanced diseaseGary Goldenberg, Omid Hamid
Clinical & Experimental Metastasis|December 8, 2021
Immunotherapy of cancer in the era of checkpoint inhibitorInderjit Mehmi, Omid Hamid
Journal of Drugs in Dermatology : JDD|November 8, 2013
Identifying patients at risk for recurrent or advanced BCCOmid Hamid, Gary Goldenberg
Expert Opinion on Biological Therapy|February 21, 2013
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapyOmid Hamid, Richard D Carvajal
Clinical Journal of Oncology Nursing|August 4, 2011
Atypical clinical response patterns to ipilimumabBlanca Ledezma, Sandra Binder, Omid Hamid
The Oncologist|March 13, 2020
Intratumoral Immunotherapy-Update 2019Omid Hamid, Rubina Ismail, Igor Puzanov
Seminars in Oncology|November 16, 2010
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockadePeter Boasberg, Omid Hamid, Steven O'Day
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2018
The Need for Neddylation: A Key to Achieving NED in Uveal MelanomaJessica Yang, Omid Hamid, Richard D Carvajal
Cancer|November 16, 2007
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignanciesSteven J O'Day, Omid Hamid, Walter J Urba
Current Oncology Reports|June 5, 2012
Mucosal melanoma: pathogenesis, clinical behavior, and managementMichael A Postow, Omid Hamid, Richard D Carvajal
Pageof 19